Rimabotulinumtoxinb - Biologic Drug Details

Summary for rimabotulinumtoxinb

Tradenames:	1
High Confidence Patents:	4
Applicants:	1
BLAs:	1
Suppliers: see list	1

Pharmacology for rimabotulinumtoxinb

Mechanism of Action	Acetylcholine Release Inhibitors
Established Pharmacologic Class	Acetylcholine Release Inhibitor

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. General brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for rimabotulinumtoxinb Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for rimabotulinumtoxinb Derived from Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Solstice Neurosciences, Llc	MYOBLOC	rimabotulinumtoxinb	Injection	103846	6,290,961	2013-12-28	Company disclosures
Solstice Neurosciences, Llc	MYOBLOC	rimabotulinumtoxinb	Injection	103846	6,632,433	2013-12-28	Company disclosures
Solstice Neurosciences, Llc	MYOBLOC	rimabotulinumtoxinb	Injection	103846	6,872,397	2013-06-10	Company disclosures
Solstice Neurosciences, Llc	MYOBLOC	rimabotulinumtoxinb	Injection	103846	6,887,476	2013-12-28	Company disclosures

3) Low Certainty: US Patents for rimabotulinumtoxinb Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Solstice Neurosciences, Llc	MYOBLOC	rimabotulinumtoxinb	Injection	103846	10,064,921	2023-10-29	Patent claims search
Solstice Neurosciences, Llc	MYOBLOC	rimabotulinumtoxinb	Injection	103846	10,076,557	2023-12-09	Patent claims search
Solstice Neurosciences, Llc	MYOBLOC	rimabotulinumtoxinb	Injection	103846	10,231,665	2033-09-20	Patent claims search
Solstice Neurosciences, Llc	MYOBLOC	rimabotulinumtoxinb	Injection	103846	10,478,478	2037-03-31	Patent claims search
Solstice Neurosciences, Llc	MYOBLOC	rimabotulinumtoxinb	Injection	103846	10,656,152	2029-01-29	Patent claims search
Solstice Neurosciences, Llc	MYOBLOC	rimabotulinumtoxinb	Injection	103846	10,722,552	2040-07-29	Patent claims search

International Patents for rimabotulinumtoxinb

Country	Patent Number	Estimated Expiration
Spain	2159624
Germany	69435253
Japan	2008056683
Canada	2300666
Spain	2332905
Canada	2164866

Supplementary Protection Certificates for rimabotulinumtoxinb

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
122008000043	Germany		PRODUCT NAME: CLOSTRIDIUM BOTULINUM NEUROTOXIN TYP A (150KD), FREI VON KOMPLEXPROTEINEN; REGISTRATION NO/DATE: 57093.00.00 20050531
122009000066	Germany		PRODUCT NAME: BOTULINUMTOXIN TYP B; REGISTRATION NO/DATE: EU/1/00/166/001-003 20010122
10C0007	France		PRODUCT NAME: TOXINE BOTULIQUE DE TYPE B; REGISTRATION NO/DATE: EU/1/00/166/001 20010122
132008901655480	Italy		PRODUCT NAME: NEUROTOSSINA DI CLOSTRIDIUM BOTULINUM DI TIPO A (150 KD) PRIVA DI PROTEINE COMPLESSATE(XEOMIN); AUTHORISATION NUMBER(S) AND DATE(S): 838, 20080409;57093.00.00, 20050531
122008000042	Germany		PRODUCT NAME: CLOSTRIDIUM BOTULINUM NEUROTOXIN TYP A (150KD), FREI VON KOMPLEXPROTEINEN; REGISTRATION NO/DATE: 57093.00.00 20050531
132008901655481	Italy		PRODUCT NAME: NEUROTOSSINA DI CLOSTRIDIUM BOTULINUM DI TIPO A (150 KD) PRIVA DI PROTEINE COMPLESSATE(XEOMIN); AUTHORISATION NUMBER(S) AND DATE(S): 838, 20080409;57093.00.00, 20050531

Rimabotulinumtoxinb Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for RimabotulinumtoxinB

Introduction to Botulinum Toxin Market

The botulinum toxin market, which includes various types such as rimabotulinumtoxinB, is experiencing significant growth driven by expanding applications in both therapeutic and aesthetic domains. Here, we will delve into the market dynamics and financial trajectory specifically for rimabotulinumtoxinB.

Global Botulinum Toxin Market Overview

The global botulinum toxin market is projected to grow substantially, with an expected market size of USD 13.4 billion by 2032, up from USD 6.6 billion in 2023, at a Compound Annual Growth Rate (CAGR) of 8.4% during the forecast period from 2023 to 2032[1].

Types of Botulinum Toxin

The market is segmented based on the type of botulinum toxin, including abobotulinumtoxinA, incobotulinumtoxinA, onabotulinumtoxinA, and rimabotulinumtoxinB. Each type has its specific applications and market share.

RimabotulinumtoxinB: Safety and Efficacy

RimabotulinumtoxinB, also known as Type B toxin, has demonstrated its safety and efficacy in treating various conditions such as facial rhytids, cervical dystonia, sialorrhea, and hyperhidrosis. This toxin has been updated in recent studies to highlight its therapeutic benefits and safety profile[5].

Therapeutic Applications

RimabotulinumtoxinB is used in several therapeutic areas:

• Cervical Dystonia: It is effective in treating muscle spasms and abnormal postures of the neck and shoulder.
• Sialorrhea: It helps in managing excessive salivation.
• Hyperhidrosis: It is used to treat excessive sweating. These therapeutic applications contribute significantly to the market growth of rimabotulinumtoxinB[5].

Aesthetic Applications

While onabotulinumtoxinA (Type A) dominates the aesthetic market, rimabotulinumtoxinB also has a niche in treating facial rhytids (wrinkles). The combination of botulinum toxin with other aesthetic treatments, such as dermal fillers, is becoming increasingly popular, which could further boost the demand for rimabotulinumtoxinB in aesthetic procedures[1].

Market Segmentation and Regional Analysis

The botulinum toxin market, including rimabotulinumtoxinB, is segmented by region:

• Americas: This region, particularly North America, has been a significant market, accounting for over 39.0% of the global market share in 2022.
• Asia-Pacific: This region is expected to grow at the fastest CAGR from 2023 to 2032, driven by increasing demand for cosmetic procedures and expanding local manufacturing capacities in countries like South Korea, China, and Japan[1][4].

Competitive Landscape

The competitive landscape of the botulinum toxin market is dynamic, with key players engaging in strategic activities such as mergers and acquisitions, partnerships, and new product launches. For instance, AbbVie’s acquisition of ImmunoGen for $10.1 billion highlights the industry’s commitment to broadening therapeutic applications and enhancing patient care[1].

Financial Trajectory

The financial trajectory of rimabotulinumtoxinB is closely tied to the overall botulinum toxin market:

• Market Size: The global botulinum toxin market is expected to reach USD 13.4 billion by 2032.
• CAGR: The market is projected to grow at a CAGR of 8.4% from 2023 to 2032.
• Regional Growth: The Asia-Pacific region is expected to be the fastest-growing market, which will likely impact the sales and revenue of rimabotulinumtoxinB positively[1].

Challenges and Opportunities

Despite the positive growth prospects, there are challenges:

• Regulatory Approvals: Delays in regulatory approvals, such as those faced by Revance Therapeutics with DaxibotulinumtoxinA for Injection, can impact the financial performance and market entry of new products[2].
• Manufacturing and Supply Chain: Reliable manufacturing and supply chain management are crucial for maintaining market presence and meeting consumer demand[2].

Key Takeaways

• Therapeutic and Aesthetic Applications: RimabotulinumtoxinB has a strong presence in both therapeutic and aesthetic markets.
• Regional Growth: The Asia-Pacific region offers significant growth opportunities.
• Competitive Landscape: Strategic activities by key players are driving market dynamics.
• Financial Growth: The market is expected to grow substantially, with a CAGR of 8.4% from 2023 to 2032.

FAQs

Q: What are the primary therapeutic applications of rimabotulinumtoxinB? A: RimabotulinumtoxinB is primarily used to treat cervical dystonia, sialorrhea, and hyperhidrosis.

Q: How does the aesthetic market influence the demand for rimabotulinumtoxinB? A: While onabotulinumtoxinA dominates the aesthetic market, rimabotulinumtoxinB has a niche in treating facial rhytids and can benefit from the growing trend of combination therapies with dermal fillers.

Q: Which region is expected to grow the fastest in the botulinum toxin market? A: The Asia-Pacific region is expected to grow at the fastest CAGR from 2023 to 2032.

Q: What are the key challenges facing the botulinum toxin market, including rimabotulinumtoxinB? A: Regulatory delays, manufacturing challenges, and supply chain issues are significant challenges.

Q: How does the competitive landscape impact the market for rimabotulinumtoxinB? A: The competitive landscape, marked by mergers, acquisitions, and new product launches, drives innovation and market expansion, benefiting rimabotulinumtoxinB.

Sources:

1. Media Market US: Botulinum Toxin Market to Surge at 8.4% CAGR from 2023-2032
2. Annual Reports: Revance Therapeutics, Inc. - Annual Reports
3. Supernus Pharmaceuticals: Dear Supernus Stockholder
4. GlobeNewswire: Insights on the Botulinum Toxins Global Market to 2026
5. PubMed: RimabotulinumtoxinB: An Update